

**NOTICE CONCERNING THE MIRANDOLA PLANT AFTER THE EARTHQUAKES IN EMILIA-ROMAGNA (ITALY)**

***Sorin Group offers its deepest sympathies to all the employees, families and companies of the region affected by the earthquakes.***

**Milan, 29 May 2012** – Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, provides an update on its manufacturing operations in Mirandola, in the Northern Italian region of Emilia-Romagna, which experienced a major earthquake on May 20, 2012 and again today, May 29.

The Company is relieved to report that no Sorin employee has been injured by the earthquakes. Sorin reports that the Mirandola facility has experienced some damage with a subsequent temporary interruption in production.

In the Mirandola plant, which is one of the seven manufacturing sites of Sorin Group (2 in Italy, 1 in France, 1 in Germany, 1 in the United States and 1 in Canada), the Company manufactures oxygenators and autotransfusion disposable kits, part of Sorin's Cardiopulmonary Business Unit. The other cardiopulmonary by-pass disposables and Sorin's entire heart-lung machine segment are manufactured in the facilities of Denver (Colorado, United States) and Munich (Germany).

The Company is currently working on the assessment of the structural integrity of the plant and on a plan to restore production. In this phase, the primary objective of Sorin Group is to guarantee safety of its employees and ensure shipment of its products to healthcare professionals worldwide.

The Company will communicate further details regarding the degree of damage, the timing and the measures necessary to resume full operation as soon as available. At this stage, Sorin Group does not expect any impact on the company's business performance in the long-term, while the short-term economic and financial impact is currently under analysis and will be promptly communicated. To this regard, Sorin Group has in place insurance policy program providing adequate coverage for both property damage and business interruption.

\* \* \*

**About Sorin Group**

Sorin Group ([www.sorin.com](http://www.sorin.com)) is a global company and a leader in the treatment of cardiovascular diseases. The company develops, manufactures and markets medical technologies and innovative therapies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, the Company focuses on three major therapeutic areas: cardiopulmonary bypass (extra-corporeal circulation and autotransfusion systems), cardiac rhythm management, and repair and substitution of heart valves. Each year, over one million patients are treated with the devices of Sorin Group in more than 80 countries.

**For further information, visit: [www.sorin.com](http://www.sorin.com), or contact:**

**Martine Konorski**  
Director, Corporate Communications  
Tel: +33 (0)1 46 01 33 78  
Mobile: +33 (0)6 76 12 67 73  
e-mail: [martine.konorski@sorin.com](mailto:martine.konorski@sorin.com)

**Francesca Rambaudi**  
Director, Investor Relations  
Tel: +39 02 69969716  
e-mail: [investor.relations@sorin.com](mailto:investor.relations@sorin.com)